Insider report: The stocks with the biggest recent sales by executives include United Airlines, Charles Schwab and NXP Semiconductors
Investors may follow moves by company executives and officers to gauge what may be happening within the businesses. However, the motivations behind executive stock sales can vary.
The data comes from VerityData and is confirmed against the original Securities and Exchange Commission filings. These are focused on discretionary activity and exclude those in which the filing explicitly says the sale was conducted pursuant to pre-planned transactions under Rule 10b5-1.
Here are some of the biggest sales from the last week:
Investor Dean DeSantis, a 10% owner of Celsius, sold 200,000 shares at an average price of $47.50 for a total of $9.5 million.
Shares of Celsius are up more than 71% this year and have rallied about 31% over the past three months. Its rally this year comes after the stock's disappointing performance in 2024, when it lost more than 50%.
Walter Bettinger, the former CEO and current co-chairman at Charles Schwab since 2022, sold 173,900 shares at an average price of $98.84 a piece. That makes for a total of $17.19 million.
Shares of the financial services company have rallied more than 16% over the past three months. The stock is up about 31% this year.
William Betz, chief financial officer of NXP Semiconductors, generated $1.54 million after selling 6,800 shares for an average price of $227.34 per share. The sale reduced Betz's holdings by 82%.
The semiconductor company's shares have gained about 12.7% over the past three months. Still, the stock is down more than 9.5% year to date.
Robert J. Simmons, chief financial officer of airline company SkyWest, sold 17,200 shares at an average price of $117.46 per share, for a total of $2.02 million.
The sale reduced Simmons' holdings by 13%. According to Verity, Simmons is one of several SkyWest executives who have sold $6 million in shares over the past 30 days.
Shares of SkyWest are up about 16.5% over the past three months and more than 9% this year.
United Airlines' chief financial officer Michael D. Leskinen unloaded 23,000 shares at an average price of $91.43 per share. The sale totaled to $2.1 million, and reduced Leskinen's holdings by 55%.
Leskinen is one of a number of United Airlines insiders selling $6.2 million in shares over the past 30 days, according to Verity. Shares of the airline operator have gained more than 16% over the past three months. The stock has had a lackluster year, however, losing more than 11% year to date.
Michael Skipworth, chief executive officer of Wingstop, sold 4,500 shares at an average price of $370.34 each, for a total of $1.67 million. The sale reduced Skipworth's holdings by 10%.
Shares of the fast-food chain have jumped about 31% over the past three months, bringing its year to date gains to nearly 25%.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
12 hours ago
- CNBC
From Starbucks to Smoothie King, restaurants seek to cash in on consumers' protein frenzy
Restaurant chains are joining in on the protein frenzy, hoping to encourage diners to pay more for extra macronutrients during a time when many consumers aren't spending as much. From "gym bros" to users of GLP-1 drugs like Ozempic, many Americans are trying to add more protein to their diets, with the goal of building or maintaining their muscle mass and feeling more satiated after meals. Moreover, diet trends that don't emphasize protein intake, such as the ketogenic diet, have fallen out of favor. "A lot of younger consumers are more proactive about their health habits, so they're looking for ways to support health now but also to support their health in the future," said Julia Mills, a food and drink analyst for market research firm Mintel. "Generation Alpha, Gen Z, millennials — these consumers are very active on social media, so they're constantly being fed this message that you need more protein, and protein helps you gain muscle and makes you stronger." Roughly a third of consumers said they loved high protein in the second quarter of 2025, up from 24% three years ago, according to Datassential, which tracks restaurant menus and consumer preferences. The trend has fueled a protein takeover in grocery store aisles, from protein-packed Eggo waffles to Khloe Kardashian's Khloud protein popcorn. But it's also hitting the menus of restaurants that are seeking ways to encourage diners to pay for premium food and drinks. Take Starbucks, for example. The coffee giant said in late July that it will roll out a cold foam packed with 15 grams of protein later this year; the regular cold foam add-on typically costs customers an extra $1.25 per drink. The new foam comes as the chain's U.S. sales have been shrinking for the past year as coffee drinkers brew their java at home or seek out trendier options. Rival Dutch Bros launched a protein coffee in early 2024 and charges customers an extra $1 for the customization. The menu addition fueled strong same-store sales growth and profits for the upstart chain. Eateries are seeking to attract diners like Jared Hutkowski, a 42-year-old director of brokerage in Harrisburg, Pennsylvania. He works out six days a week and tries to hit his daily protein goal to improve his physique and overall health. When he dines out, he tries to maximize his protein, although he sometimes goes for pizza anyway. "The biggest factor is what I am in the mood for that day, and then I normally try and select a meal that has a least a serving of some type of protein in it," Hutkowski said. This year, 28.4% of U.S. restaurant menus call out "protein," up from 5.9% a decade ago, according to Datassential. And the trend looks like it has staying power. Datassential predicts that by 2029, more than 40% of eateries will highlight protein on their menus. "Protein is one of those things that's never been vilified, because no one's ever said that eating too much protein can be bad for you," Mintel's Mills said. In the short term, consuming more protein than your body needs likely won't cause health issues, but in the long term, it could cause kidney problems, according to Diane Han, a registered dietitian based in San Francisco and the founder of Woking Balance Wellness. The recommended daily amount of protein intake varies by body weight but is roughly 46 grams for women and 56 grams for men, according to the Centers for Disease Control and Prevention. For restaurants, protein's step change happened several years ago. In 2021, protein only had a menu penetration of 11.5%; by 2022, more than a quarter of restaurant menus used the term, based on Datassential data. That year, Dine Brands' IHOP, for example, introduced pancakes with 18 grams of protein per flapjack. Fast-casual eateries are the restaurant segment most likely to call out protein on their menus, thanks to the common practice of asking customers to pick their protein or offering to double their portion, according to Datassential. Fast-casual salad chain Sweetgreen introduced a line of "protein plates" in late 2023 as part of an effort to introduce more hearty options for dinner customers. The menu addition has helped the company grow its dinner business from 35% of sales to about 40%, executives said in March. Many restaurants are also leaning into U.S. consumers' desire for convenience. Accessibility may be why Datassential found that consumers tend to prefer protein-packed beverages. For Smoothie King, protein has been a menu staple since its founding more than 50 years ago. But in October, the chain took one step further, launching a menu aimed at consumers who take GLP-1 drugs for weight loss or diabetes. The rapid weight loss that can occur from the medications can cause muscle mass to drop, so doctors often advise patients to increase their protein intake to maintain their muscle. "It's a convenient, on-the-go way to get in your protein that you're looking for in your diet," said Lori Primavera, Smoothie King's vice president of research and development and product marketing. Many restaurants are also choosing to highlight existing protein-packed options, rather than adding new menu items that would slow down kitchens or add to much complexity to their operations. For example, Panda Express introduced its own protein plates earlier this year. The line, created in partnership with a registered dietitian, includes pre-existing menu items but packages them as a balanced meal, highlighting protein and fiber content. Chipotle Mexican Grill employed a similar strategy back in 2019 when it introduced "lifestyle bowls," marketed to fit different dietary goals, like the paleo diet or offering double protein. Likewise, in July, Chick-fil-A put the spotlight on its own high-protein options in a company blog, highlighting its grilled nuggets and the Cool Wrap, which features a grilled chicken breast, cheese and lettuce in a tortilla. But for the eateries that want to add new menu items, nachos with a choice of protein, restaurant-made protein bars and egg dishes that highlight high protein content are all increasingly popular options, according to Datassential trendologist Claire Conaghan. Eggs are one reason why breakfast, brunch and lunch eatery First Watch has always been "protein forward," CEO Chris Tomasso told CNBC. The chain hasn't adjusted its menu specifically to address consumers' demand for more protein, but TikTok influencers have highlighted how to order a high-protein meal when visiting its restaurants. "We hope that continues to be a trend because we're right down the middle of the fairway on that," Tomasso said. Of course, protein isn't the only way to win over health-conscious consumers. Hutkowski said his primary issue with eating at restaurants is that most of the food is cooked in oils, butter and heavy greases that rapidly add to his intake of fats for the day. "A restaurant finding cleaner ways to cook would be much more attractive to me than overly loaded protein dishes," he said.
Business Insider
18 hours ago
- Business Insider
How Wall Street Missed the Bigger Picture on Novo Nordisk Stock (NVO)
Once seemingly unstoppable, Novo Nordisk (NVO) stock is now caught in a storm. Fierce competition in the GLP-1 space—especially from cheaper compounders—has taken a toll on its U.S. market share, and there's growing skepticism around the strength and pace of its growth story. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. To turn things around, investors are now hanging hopes on favorable litigation outcomes and smart pricing decisions that can protect margins and help the company reclaim lost ground, all while delivering on its now more conservative guidance. The bright side, though, is that Novo Nordisk still maintains rock-solid fundamentals: its profit margins lead the pack, cash flow generation is healthy, and it trades at what looks like de-risked multiples, backed by one of the best balance sheets in the sector — second only to Johnson & Johnson (JNJ). Given this disconnect between strong fundamentals and the market's bearish mood, I rate NVO as a Buy. Still, the stock could remain under pressure in the short to mid-term as the market struggles to price in the uncertainty tied to the ongoing litigation mess. Why Novo Nordisk is Under Pressure Novo Nordisk went from heaven to hell in about two years, soaring 110% from $63 per share in 2023 to over $140 by mid-2024, only to then plunge 66% down to below $50. The stars of the show were Ozempic and Wegovy, which made Novo Nordisk a leader in the obesity drug market. But Novo Nordisk started losing ground as competitors, especially Eli Lilly (LLY) with Mounjaro and Zepbound, came onto the scene—both showing clinical results with even greater weight loss than Ozempic and Wegovy. This competition hit Novo's top line hard, slowing revenue growth from 35% in 2023 to 17.3% in 2024, while operating income growth dropped from 42% to 25.3% over the same period. Recently, Novo Nordisk lowered its 2025 outlook, now expecting revenue growth only in the mid-single digits and operating profit growth between 10% and 16%. That's a major slowdown compared to the heady days fueled by Ozempic and Wegovy. The U.S. market remains the primary source of weakness, with growth slowing sharply compared to international markets, which are still on the rise. On the bright side, Novo still expects over $5.8 billion in free cash flow for 2025, showing a resilient core business. That translates to a forward FCF yield of about 3.5% today—well above Eli Lilly's current 0.5% yield—suggesting a fairly competitive valuation despite the pressures from compounders. And the patient base behind it all is real and solid. NVO's Compounder Problem and Legal Battles Speaking of compounders, this has been Novo Nordisk's biggest headache in its U.S. operations. The company has been hit hard by unauthorized compounder versions of its GLP-1 drugs, sold through alternative providers like Hims & Hers (HIMS) at lower prices, stealing market share—especially among more price-sensitive customers. It's important to note that Hims & Hers, once a distribution partner for Novo Nordisk, isn't selling FDA-approved generics, but instead is exploiting a legal loophole called the compounding pharmacy exception. This allows pharmacies to create injectable versions when there's a shortage of the original product, which has been the case for Wegovy and Ozempic. So, the situation is a bit murky but not exactly illegal. At least not yet. Novo Nordisk hasn't been sitting still and has taken legal action to shut down these compounders. But progress has been slow, and because of the uncertainty around how this will play out, management hasn't given clear guidance for 2026. And as we know in the stock market, uncertainty often hurts more than bad news, so NVO stock has taken a hit. The Opening Act of Novo Nordisk's Market Fight If this dispute ends in Novo Nordisk's favor, there's a lot on the table. Estimates suggest that around one million patients in the US are currently using compounded GLP-1 drugs. If these are removed from the market, as many as three-quarters could shift to branded options—though Novo might only capture a third of that. Still, even that slice would represent a major tailwind for the company moving forward. The tricky part is that regulators seem reluctant to take cheaper GLP-1 alternatives off the market. That puts Novo Nordisk in a tough spot—potentially needing to cut prices (and eat into margins) just to make regulators more comfortable, hoping to make up for it later by regaining market share. On a brighter note, Novo recently scored a big win: its obesity drug is now the only GLP-1 included in CVS's (CVS) national coverage template, which should boost both volume and visibility. While Lilly's Zepbound is, on average, more effective than Wegovy, drug superiority isn't the only factor that determines market dominance. Side effects and, just as importantly, distribution channels play a huge role in driving adoption. A Quality Name at a Discount Considering Novo Nordisk is still growing revenue at double-digit rates, has a 3.3% dividend yield, and maintains net profit margins of 34.5% —around 12% higher than Eli Lilly's and arguably better than any other major biotech—the market's reaction to its guidance cut seems somewhat overdone. The stock is trading at just 11.6x forward earnings and 11x cash flows—roughly 30% and 21% below the industry average, respectively. That looks like a discount that might not be entirely justified for a company that, while facing some headwinds and slowing growth, has consistently delivered strong financials and now seems to be trading at heavily de-risked multiples. What is the Forecast for NVO Stock? On Wall Street, NVO stock carries a Moderate Buy consensus rating based on two Buy, three Hold, and zero Sell ratings over the past three months. NVO's average stock price target of $73 implies almost 50% upside potential over the next twelve months. Battling Compounders on the Road to Recovery Novo Nordisk is now in a position where it needs to prove it can sustain healthy growth despite competition from lower-priced compounders, while also expanding its share in the massive and growing obesity treatment market. The sluggish momentum from its highs and the recent earnings update, which lowered its annual guidance, have naturally pushed the market to revise its growth expectations downward. The investment case depends on the results of ongoing litigation, pricing strategies, and regulatory decisions, all of which will help clarify the path for future growth. But even with growth slowing, the fundamentals remain solid—margins are better than peers', and the stock trades at valuations that feel sufficiently de-risked. For long-term investors, it looks like a good buying opportunity.
CNBC
a day ago
- CNBC
Madrigal Pharmaceuticals CEO: We're positioned for decades of growth
Bill Sibold, Madrigal Pharmaceuticals CEO, joins 'Fast Money' to discuss Q2 earnings results, the weight loss space and their GLP-1 strategy.
